drugset / Trial / NCT01489254

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254

Phase 3 Completed 794 enrolled Synthon BV
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis

Timeline

Start
2011-10
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Glatiramer Acetate Small molecule 20 mg Subcutaneous

Indications